COMPLETED

Cognitive Enhancement in Depression (The COG-D Study)

Conditions

Aging Depression Cognitive Symptom geriatrics elderly cognition memory tDCS cognitive training cognitive remediation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will investigate whether transcranial direct current stimulation (tDCS) enhances the effects of computerized cognitive training in older adults with recurrent depression (2 or more lifetime episodes; either current or within past 3 years).

Official Title

Non-invasive Neuromodulation to Enhance Targeted Cognitive Remediation in Older Adults With Depression

Quick Facts

Study Start:2023-02-08

Study Completion:2025-08-18

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT05400512

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:60 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Age 60+ years * Diagnosis of a current or past (within last 3 years) depressive episode (e.g., Major Depressive Disorder (MDD), Persistent Depressive Disorder (PDD)) using Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria * In total, participants must have 2 or more lifetime depressive episodes to be considered "recurrent" * Either stable antidepressant regimen for at least 6 weeks or no current antidepressant treatment * Evidence of subjective cognitive complaints on the Everyday Cognition Scale (ECog) * English fluency	* Other Axis I psychiatric conditions via the DSM-5, except for anxiety symptoms occurring in a depressive episode * Acute suicidality on clinical evaluation * Acute grief * History of alcohol use disorder or substance use disorder in last 12 months * Currently taking medications that would significantly interact with tDCS effects (such as sodium channel blockers or anticonvulsants) * Neurological disorders (e.g., dementia, stroke, seizures, traumatic brain injury, Parkinson's disease) * Montreal Cognitive Assessment (MoCA) score \< 23 * Primary amnestic cognitive profile (\>1.5 standard deviations (SDs) below demographically-adjusted mean on National Alzheimer's Coordinating Center (NACC) memory measures in context of otherwise normal cognitive profile) * Any physical or intellectual disability affecting ability to complete assessments * Unstable medical illness needing urgent treatment * MRI contraindications * Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in last 2 months * Current involvement in psychotherapy * Current involvement in other research studies (including but not limited to: neuromodulation \[TMS or tDCS\] or investigational drug studies)

Inclusion Criteria

Exclusion Criteria

* Age 60+ years
* Diagnosis of a current or past (within last 3 years) depressive episode (e.g., Major Depressive Disorder (MDD), Persistent Depressive Disorder (PDD)) using Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria
* In total, participants must have 2 or more lifetime depressive episodes to be considered "recurrent"
* Either stable antidepressant regimen for at least 6 weeks or no current antidepressant treatment
* Evidence of subjective cognitive complaints on the Everyday Cognition Scale (ECog)
* English fluency

* Other Axis I psychiatric conditions via the DSM-5, except for anxiety symptoms occurring in a depressive episode
* Acute suicidality on clinical evaluation
* Acute grief
* History of alcohol use disorder or substance use disorder in last 12 months
* Currently taking medications that would significantly interact with tDCS effects (such as sodium channel blockers or anticonvulsants)
* Neurological disorders (e.g., dementia, stroke, seizures, traumatic brain injury, Parkinson's disease)
* Montreal Cognitive Assessment (MoCA) score \< 23
* Primary amnestic cognitive profile (\>1.5 standard deviations (SDs) below demographically-adjusted mean on National Alzheimer's Coordinating Center (NACC) memory measures in context of otherwise normal cognitive profile)
* Any physical or intellectual disability affecting ability to complete assessments
* Unstable medical illness needing urgent treatment
* MRI contraindications
* Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in last 2 months
* Current involvement in psychotherapy
* Current involvement in other research studies (including but not limited to: neuromodulation \[TMS or tDCS\] or investigational drug studies)

Contacts and Locations

Principal Investigator

Sarah M. Szymkowicz, PhD

PRINCIPAL_INVESTIGATOR

Vanderbilt University Medical Center

Study Locations (Sites)

Vanderbilt University Medical Center

Nashville, Tennessee, 37212

United States

Collaborators and Investigators

Sponsor: Vanderbilt University Medical Center

Sarah M. Szymkowicz, PhD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-02-08

Study Completion Date2025-08-18

Study Record Updates

Study Start Date2023-02-08

Study Completion Date2025-08-18

Terms related to this study

Keywords Provided by Researchers

geriatrics
aging
elderly
cognition
memory
depression
tDCS
cognitive training
cognitive remediation

Additional Relevant MeSH Terms

Aging
Depression
Cognitive Symptom